A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-14 and is reviewed periodically as new material appears.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
In addition to the base stations, the Index's headset and controllers feature Inertial Measurement Units (IMUs) that provide rapid updates on movement and orientation. The IMUs track motion at several hundred Hz, but are prone to drift. The Lighthouse system compensates for this drift by using the base stations’ lasers to provide a precise positional reference, integrating this data with the IMU information to maintain accurate tracking even during fast movements. This combination of external base stations and internal sensors on the tracked devices ensures the Valve Index provides accurate and responsive tracking performance.
The panel has come to some controversy, however; on July 20, 2010, one of the panelists was discovered to have been a paid speaker for GlaxoSmithKline, arousing questions of a conflict of interest. This panel member was one of the three who voted to keep Avandia on the market with no additional warning labels. In 2011 the FDA has decided on revising its prescribing information and medication guides for all rosilitazone containing medicines. The US label for rosiglitazone (Avandia, GlaxoSmithKline) and all rosiglitazone-containing medications (Avandamet and Avandaryl) now include the additional safety information and restrictions. The revised labels restrict use to patients already taking a rosiglitazone-containing medicine or to new patients who are unable to achieve adequate glycemic control on other diabetes medications and to those, who in consultation with their healthcare provider, have decided not to take Actos (pioglitazone) or other pioglitazone-containing medicines for medical reasons. In June 2013 an FDA Advisory Committee reviewed all available data, including a re-adjudicated RECORD trial, found no evidence of increased cardiovascular risk with Avandia, and voted to remove the restrictions on Avandia marketing in the United States. In November 2013, the US FDA removed these marketing restrictions on the product. Under the FDA's instruction, Avandia's maker, GlaxoSmithKline, had funded the Duke Clinical Research Institute to re-analyze the raw data from the study.
The BBC said at the time, "The tumbling reputation of the former KLA was to have a disastrous effect on the PDK because of the perceived overlap between its political leadership and post-KLA organised crime." A 2008 analysis of organised crime in Kosovo prepared by the German intelligence service BND and a confidential report contracted by the German military accused Thaçi, Ramush Haradinaj, and Xhavit Haliti, the majority leader of the Kosovo parliament, of far-reaching involvement in organised crime. The BND wrote: "The key players (including Haliti, Haradinaj, and Thaçi) are intimately involved in inter-linkages between politics, business, and organised crime structures in Kosovo." The report accused Thaçi of leading a "criminal network operating throughout Kosovo" by the end of the 1990s. The BND report accused Thaçi of having contacts with the Czech and Albanian mafias. It said that he, together with Haliti, ordered killings by a professional hit man, 'Afrimi', responsible for at least 11 contract murders. Thaçi has faced other accusations, such as the involvement in the lucrative heroin trade in the 1990s when officers of the Kosovo Liberation Army and their backers were moving staggering quantities of narcotics through an underworld network into Central Europe. Police had long suspected that illegal narcotics were fueling the revolt in Kosovo. A report to the Council of Europe, written by Dick Marty, issued on 15 December 2010 states that Hashim Thaçi was the leader of the "Drenica Group" in charge of trafficking organs taken from Serbian prisoners.
Sources: en.wikipedia.org
== Proteins == The two main components of the soybean important in tofu making are the 11S component, containing glycinin, and the 7S subunit, containing hemagglutinins, lipoxygenases, b-amylase, and β-conglycinin. The major soy protein components, in the two fractions that make up 65–85% of the proteins in soybeans, include glycinin and β-conglycinin. The soybean protein consists of many different subunits, which are sensitive to heat, pH, and ionic strength and become unevenly distributed among soluble and particulate fractions due to hydrophilic and hydrophobic interaction because of the amino acid composition.
As harvested, the green seed pods contain vanillin in the form of glucovanillin, its β-D-glucoside; the green pods do not have the flavor or odor of vanilla. Vanillin is released from glucovanillin by the action of the enzyme β-glucosidase during ripening and during the curing process. After being harvested, their flavor is developed by a months-long curing process, the details of which vary among vanilla-producing regions, but in broad terms it proceeds as follows: First, the seed pods are blanched in hot water, to arrest the processes of the living plant tissues. Then, for 1–2 weeks, the pods are alternately sunned and sweated: during the day they are laid out in the sun, and each night wrapped in cloth and packed in airtight boxes to sweat. During this process, the pods become dark brown, and enzymes in the pod release vanillin as the free molecule. Finally, the pods are dried and further aged for several months, during which time their flavors further develop. Several methods have been described for curing vanilla in days rather than months, although they have not been widely developed in the natural vanilla industry, with its focus on producing a premium product by established methods, rather than on innovations that might alter the product's flavor profile.
=== Cultural aspects of exhumation === Frequently, cultures have different sets of exhumation taboos. Occasionally these differences result in conflict, especially in cases where a culture with more lenient exhumation rules wishes to operate on the territory of a different culture. For example, U.S. construction companies have run into conflict with Native American groups that have wanted to preserve their burial grounds from disturbance. In Southern Chinese culture, graves are opened after a period of years. The bones are removed, cleaned, dried, and placed in a ceramic pot for reburial (in Taiwan), or in a smaller coffin and to be reburied in another location (in Vietnam). The practice is called jiǎngǔ(撿骨) in Taiwan, or Bốc mộ(卜墓) in Vietnam "digging up bones" and is an important ritual in the posthumous "care" of children for their deceased parents and ancestors. Jewish law forbids the exhumation of a corpse. The majority of Muslim jurors maintain that an individual buried in a mosque must be exhumed and that offering prayers in such a mosque renders the prayer invalid. Jurists, however, hold that mosques built around already existing graves are to be demolished. In England and Wales once the top of a coffin has been lowered below ground level during a burial, raising the coffin again, for any reason, is considered exhumation regardless of the cause. Even if further work is necessary to properly fit the casket into the grave without further, the Home Office must to be notified and a full investigation undertaken.
== Approval == The patch was granted a license from the European Medicines Agency in July, and is available on Britain's National Health Service from March 2007. However, in December 2004 the United States the 14-member Food and Drug Administration (FDA) advisory committee, plus voting consultants, for Reproductive Health Drugs unanimously rejected Procter and Gamble's fast-track request for Intrinsa citing concerns about off-label use. In Canada, post-menopausal women have been able to obtain government-approved testosterone treatment since 2002. In Australia, post-menopausal women can use Organon testosterone implants which have to be surgically inserted and last from three to six months.
Sources: en.wikipedia.org
== Symptoms == Prodromal symptoms are typically fever, cough, and rhinorrhea. BACM symptoms that follow are most frequently calf pain, gait complaints, and inability to walk. The condition is self-limited and full restitution can be expected. In very rare cases, however, rhabdomyolysis may develop. Affected are preschool and school-age children with a male predominance. In one study, the median age was 6 years (range 2–13.2 years). It has been estimated that BACM has an incidence of 2.69 cases per 100,000 children (<18 years) during epidemic seasons and 0.23 cases during non-epidemic seasons.
September 15 The US military announces that it destroyed two Iranian small boats the day before following an IRGC attempt to capture one of its Navy drones patrolling the Strait of Hormuz. A federal judge blocks the Kennedy Center from adding President Trump's name to the building or its grounds without congressional approval. Hours later, the centre's board votes to close most of the venue for up to two years for renovations. September 16 Three people are killed in a helicopter crash in Chatsworth, Los Angeles, including NBC News journalists Eliana Moreno and George Marciniw. The Federal Reserve raises interest rates for the first time in three years, from 3.5%-3.75% to 3.75%-4%. A memorandum of understanding is signed with the Pakistan army by US drone maker Powerus, which is set to merge with a firm backed by Trump’s sons. The Trump administration announces that Palestinian president Mahmoud Abbas and his delegation are barred from attending the UN General Assembly in New York, accusing them of breaching US law. September 17 The House of Representatives passes sweeping Russia sanctions legislation by a vote of 262-159. Flash flooding in the Navajo Nation kills three. A UN mission finds grounds to believe that the US committed war crimes in the 2026 Minab school attack and the 2026 Lamerd sports hall attack.
=== Nuclear weapons decommissioning === Waste from nuclear weapons decommissioning is unlikely to contain much beta or gamma activity other than tritium and americium. It is more likely to contain alpha-emitting actinides such as Pu-239 which is a fissile material used in nuclear bombs, plus some material with much higher specific activities, such as Pu-238 or Po. In the past the neutron trigger for an atomic bomb tended to be beryllium and a high activity alpha emitter such as polonium; an alternative to polonium is Pu-238. For reasons of national security, details of the design of modern nuclear bombs are normally not released to the open literature. Some designs might contain a radioisotope thermoelectric generator using Pu-238 to provide a long-lasting source of electrical power for the electronics in the device. It is likely that the fissile material of an old nuclear bomb, which is due for refitting, will contain decay products of the plutonium isotopes used in it. These are likely to include U-236 from Pu-240 impurities plus some U-235 from decay of the Pu-239; due to the relatively long half-life of these Pu isotopes, these wastes from radioactive decay of bomb core material would be very small, and in any case, far less dangerous (even in terms of simple radioactivity) than the Pu-239 itself.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.